Summary
- A product notice sells assurance after the sale. It buys a verified destination, a decision record, a search trail, support capacity and a way for counterparties to separate official safety information from rumor, marketing and fraud.
- The cost is not the cost of posting a PDF. J&J's public filings and policies point to quality review, medical-safety judgment, legal exposure, regulatory communication, archiving, cybersecurity, domain control, customer response management and anti-counterfeit work as part of the same trust expense.
- Strong public evidence supports the claim that notices are material to risk control: the 2025 annual report links safety concerns and recalls to withdrawals, regulatory action, litigation expense, sales decline and reputational damage, while FDA guidance defines what a recall communication must accomplish.
- Company and technical evidence suggests that official, searchable and durable digital destinations are valuable, but public evidence does not prove the return on that spending. The missing numbers are notice readership, response rates, spoofing losses avoided, support-load reduction and patient-outcome gains.
The notice is the product after the product
The economic unit here is not a medicine vial, an implant, a contact lens, a surgical pack or a software update. It is the product notice: the official message that tells a customer or counterparty what has changed after the product has left the factory. In a lightly regulated market, a notice may be little more than a service announcement. In health products it is closer to a second product, because it is consumed under pressure, interpreted by professionals, stored by institutions and later examined by lawyers, regulators and auditors. It has to be clear enough to act on, narrow enough not to create needless alarm, broad enough not to miss affected users and durable enough to survive long after the commercial conversation has moved on.
Johnson & Johnson is a useful case because its public evidence shows both sides of the problem. Its 2025 annual report reports $94.2 billion of consolidated sales, nearly $34 billion of MedTech sales, 51 Innovative Medicine approvals across major markets and 15 major MedTech products launched in major markets (https://www.jnj.com/download/johnson-johnson-2025-annual-report). Those figures describe scale. Scale is the reason product notices become infrastructure rather than clerical work. A notice attached to one lot, one implant system or one medicine label can travel through hospitals, wholesalers, clinics, pharmacies, purchasing departments, insurers, patient forums, search engines and regulator databases. If the notice is ambiguous, hidden, hard to verify or easily spoofed, the uncertainty spreads along the same channels as the product.
A generic profile would miss the narrower economics. What does an official product notice actually sell or buy? Why is the notice expensive even before the cost of a recall, repair or refund is counted? And does public evidence prove that this cost is worth paying?
The first answer is that a notice buys a reduction in transaction uncertainty. A hospital that bought a device does not merely need the manufacturer to say that a product exists. It needs a verified statement about whether a specific lot, serial number or product code is affected; whether use should stop; whether inventory should be quarantined; whether patients already treated need follow-up; whether the message came from the manufacturer; and whether the notice can be shown later to an internal safety board, a regulator or a court. FDA guidance on electronic distribution of product information says recall communication should identify the affected product, explain the reason and hazard, give instructions and provide a way for recipients to respond (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-electronic-means-distribute-certain-product-information). That is a commercial specification as much as a public-health instruction.
The second answer is that a notice is expensive because it must be trusted at several layers at once. Medical safety has to know what the evidence means. Quality teams have to know which lots, product codes or production routes are implicated. Legal review has to make the public words accurate without making them uselessly cautious. Regulatory affairs has to align with FDA, European, national and local requirements. Customer support has to absorb calls from people who may not have read the whole notice. Security teams have to make sure the destination is not easily confused with a spoofed page. Records teams have to preserve the notice. Search and web teams have to make it findable. The cost is an institutional system, not a page view.
The third answer is weaker. Public evidence strongly supports the need for notices as risk control. It does not prove the private return on investment. The public can see regulatory expectations, J&J governance statements, domain-registration evidence, recall examples and risk-factor disclosures. It cannot see response-rate data, avoided harm, support savings, counterfeit diversion prevented or the internal comparison between a weak notice and a strong one. The thesis is therefore supported as a risk-management claim and suggested as a trust-economics claim, but it is not proven as a quantified value claim.
What a notice buys for customers and counterparties
A product notice buys time. It shortens the interval between a signal and a practical decision. That is the simple case for digital notice infrastructure. FDA's electronic-communications guidance says electronic methods can shorten the time between an event and public knowledge, can be more efficient and timely than traditional mail and can provide delivery or read-confirmation mechanisms (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-electronic-means-distribute-certain-product-information). In health products, time is not just a convenience. The economic value of one day saved depends on the product and the hazard: a mislabeled consumer product, a contact-lens defect, a surgical consumable issue and a medicine safety update create different urgency profiles. But all of them require recipients to decide before complete certainty is available.
A notice also buys specificity. A hospital, distributor or pharmacy does not need a brand statement. It needs product code, lot, serial number, expiration date, geography, status and instruction. The value lies in reducing the search cost inside the buyer's own systems. If a notice tells a supply-chain manager which inventory to quarantine, it saves labor. If it tells a clinician which patients may require follow-up, it saves medical-review time. If it tells a purchasing group that a product can continue to be used outside a specified range, it prevents unnecessary substitution. A vague warning shifts cost to the customer; a precise notice absorbs cost at the manufacturer and turns it into usable information.
This is why product notices are a commercial trust instrument. The customer paid for the product before the notice existed. The notice is part of the continuing bargain that the manufacturer will maintain an informational connection to the product after shipment. The connection matters most when the customer has already embedded the product in a workflow. A medicine sits inside formularies and prescribing systems. A device sits inside operating-room routines and maintenance procedures. A contact lens sits inside optometry channels and patient habits. A surgical pack sits inside procedure scheduling. The customer is buying not only the item but also the right to be told, accurately and officially, when later facts change the use case.
Counterparties buy something different. Regulators buy evidence that the manufacturer can identify affected products, notify affected accounts and measure whether the message moved. Insurers and health systems buy a defensible record that they acted on official information. Distributors buy instructions that let them stop shipment without improvising. Physicians buy a compact statement that can be placed beside clinical judgment. Patients buy a signal that does not require them to choose between a social-media rumor and a call-center script. The notice is therefore a shared commercial object. Each party consumes a different part of it, but all of them need the same qualities: official origin, precise scope, readable instructions and durable access.
The notice also buys a boundary against rumor. Product concerns often become public before a company can prove root cause. The 2025 annual report says product efficacy or safety concerns, whether or not based on scientific evidence, can lead to withdrawals, recalls, regulatory action, declining sales, reputational damage, increased litigation expense and share-price impact (https://www.jnj.com/download/johnson-johnson-2025-annual-report). That language is important because the market does not wait for perfect proof. Once a concern exists, the economic question becomes whether the company can publish an official account that is specific enough to be trusted and stable enough to be cited. If it cannot, other narratives fill the gap.
There is a further buying decision hidden inside the notice. Customers are deciding whether to continue treating the manufacturer as a reliable counterparty. A well-run notice does not make the underlying safety problem disappear. It can, however, show that the company knows what product is in the field, can identify the affected scope, can say what is unknown, can update the record, and can provide a route for questions. That is why the notice has value even when the news is bad. It turns a failure into a managed obligation.
The cost sits in judgment before publication
The cheapest product notice is the one no serious health-products company can use: a short statement posted quickly with broad wording and little evidence. It is cheap because it transfers almost every hard question to the recipient. The costly notice does the opposite. It asks the manufacturer to decide what is affected, what is not affected, what the hazard is, whether the language is medically fair, what action should be taken, and how to update the message if facts change.
J&J's public quality position describes a formal quality system, not an informal response habit. It says the company's quality approach includes quality policies and standards, quality risk management, compliance monitoring through audits and inspections, escalation procedures, continuous improvement, acquisition integration and training (https://www.jnj.com/policies-reports/our-position-on-quality-and-compliance). It also says quality management is functionally independent from commercial interests and that Quality Review Boards decide independently of commercial considerations whether actions are needed to correct or recall a product. Patient and consumer safety is described as superseding other factors in that decision.
That independence is a cost. It means product-notice decisions cannot be optimized only for sales preservation. They have to pass through functions that may slow publication in order to avoid inaccuracy or narrow the scope in order to avoid over-warning. The expensive part is not merely review by a lawyer. It is the reconciliation of evidence, product history, regulatory duty and operational feasibility. A notice that moves too slowly can harm customers. A notice that moves too broadly can create shortages, unnecessary procedure delays or unnecessary patient anxiety. A notice that moves with weak evidence can damage credibility and later become a litigation exhibit. A notice that omits a material fact can do worse.
J&J's patient-safety position shows the same structure from a medical angle. It says manufacturers must demonstrate that product benefits outweigh risks starting in development and continuing once products are available to the public, and it describes an Office of the Chief Medical Officer with independent medical-safety responsibilities across the product life cycle (https://www.jnj.com/policies-reports/our-position-on-patient-safety). It also describes pharmacovigilance as the detection, assessment, understanding and prevention of adverse events or other drug-related problems, with staff duties to report safety signals and adverse events as required by law. That kind of system is expensive because it makes the notice a product of surveillance, not publicity.
Legal cost enters because notice language sets the boundary between disclosure and admission, between instruction and promotion, and between scientific uncertainty and commercial confidence. FDA's electronic-communication guidance says recall communications should be concise, should not contain irrelevant qualifications or promotional materials, and should be evaluated for whether the notice was received, read, understood or followed (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-electronic-means-distribute-certain-product-information). That last point makes a notice more like a controlled operational record than a public statement. A company must be able to show not only that it said something, but that it had a strategy for whether the message reached the relevant accounts.
Compliance cost also rises with geography. J&J's annual report describes operations under FDA and international counterparts, requirements to comply with medical-device reporting rules and the European Union's Medical Devices Regulation, and increased enforcement activity by regulators (https://www.jnj.com/download/johnson-johnson-2025-annual-report). A global notice has to map a product concern onto different legal regimes, languages, distribution chains and health-authority expectations. A single public page may be the visible output, but the hidden work is a matrix of jurisdictions and product categories.
The result is a paradox. Customers want fast notices because safety information decays in value when delayed. Companies need reviewed notices because an inaccurate message can create its own harm. The product notice is expensive because it has to be fast and defensible at once. That is the operating surface where trust becomes a cost.
Official destination is part of the safety message
Digital notices only have value if recipients can identify the official destination. A notice that lives on a fragile page, a confusing subdomain or a platform with weak identity cues creates a new problem: the reader has to authenticate the messenger before interpreting the message. That is why DNS delegation, RDAP accountability and abuse-contact economics are not side issues. They are part of the product-notice market.
Public RDAP data for jnj.com, queried on July 5, 2026, shows the domain registered in 1993, with Key-Systems GmbH listed as registrar, multiple status codes including client transfer prohibited, client update prohibited, server transfer prohibited and server update prohibited, and a nameserver set using NS1 and jnjdns.com infrastructure (https://rdap.verisign.com/com/v1/domain/JNJ.COM). The registrar RDAP record shows an abuse contact and redacted registrant and technical data, with a New Jersey country-and-state marker in the registrant address fields (https://rdap.rrpproxy.net/domain/JNJ.COM). RDAP data for jnjmedtech.com shows a 2021 registration, Key-Systems as registrar, transfer/delete protection statuses and the same broad nameserver pattern (https://rdap.verisign.com/com/v1/domain/JNJMEDTECH.COM).
Those facts do not prove that any individual notice is good. They show that the official web destination is itself administered through a control layer. ICANN explains that client transfer prohibited can help prevent unauthorized transfers resulting from hijacking or fraud, and client update prohibited can help prevent unauthorized updates (https://www.icann.org/resources/pages/epp-status-codes-2014-06-16-en). The distinction matters. A safety notice can be carefully written and still fail if the domain is hijacked, if a confusing spoof outranks the official page in search, or if customers cannot tell which message came from the manufacturer.
The branded .jnj space adds another control signal. The IANA RDAP bootstrap file maps the .jnj top-level domain to CentralNic's RDAP service, and a public RDAP query for jnj.jnj shows the branded domain registered in 2017 with Key-Systems, nameservers overlapping the jnjdns and NS1 pattern, redacted registrant data and registrar abuse-contact information (https://data.iana.org/rdap/dns.json; https://rdap.centralnicregistry.com/jnj/domain/JNJ.JNJ). A branded top-level domain is not a public-health guarantee, and J&J's main public presence remains on conventional domains. But the existence of a controlled namespace is consistent with a broader corporate approach: official identity is an asset that must be operated, renewed and defended.
The economics of an official destination are easiest to see during a recall or safety scare. A recipient may arrive by search, email, QR code, regulator database, distributor forwarding, social media or a colleague's message. Each route can distort context. The official destination must therefore be searchable and stable. It must allow a recipient to verify the latest version, not a clipped screenshot. It must let a search engine and a hospital knowledge system point to the same durable location. It must keep enough historic material to make past instructions reconstructable. And it must provide a contact path if the recipient has inventory, adverse-event information or fraud evidence.
J&J's own cybersecurity language supports this identity argument. Its information-security position says information assets include manufacturing information, customer data and systems required for the proper functioning of the company, and that such assets are under constant threat from malicious cyberattacks (https://www.jnj.com/policies-reports/our-position-on-information-security). The same policy says the company maintains response and recovery capabilities, authority notification processes and controls across manufacturing, distribution and connected or wearable medical devices. A product notice sits directly across these domains. It is a piece of information that can influence customer action; therefore it must be protected as more than communications copy.
The vulnerability-reporting page makes the point even more plainly. J&J says its cybersecurity program is designed to safeguard devices, data, products, services and infrastructure, and it provides a process for security researchers to report weaknesses in infrastructure, websites, public APIs, applications and products (https://www.jnj.com/coordinated-vulnerability-disclosure-statement). This is company evidence rather than independent outcome proof. Still, it is consistent with the thesis: the credibility of digital product information depends on the security of the channels that carry it.
Searchability is a compliance feature, not decoration
The product notice has to be found by people who are not reading the manufacturer's site every morning. That makes searchability an economic feature. A hospital buyer may search by product name. A nurse may search by symptoms. A distributor may search by lot. A patient may search by brand and "recall." A regulator may search by recalling firm. A journalist may search by date. A lawyer may search years later. A robust notice architecture has to meet all of those query types without turning the page into promotional material.
FDA's public recall page says its list contains information gathered from press releases and other public notices about certain recalls of FDA-regulated products, that not all recalls have press releases or appear on that page, and that entries remain on the FDA website for three years before being archived (https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts). That creates a two-layer archive problem. The regulator may preserve a record, but the manufacturer still needs its own durable public material because customers will search both official government pages and company pages. If the company destination disappears, the market is left with fragments: FDA entries, press summaries, old emails and third-party pages with uneven accuracy.
The FDA Enforcement Report is broader. FDA says the report includes all recalls it monitors once classified, and may list some recalls before classification when the agency determines a firm action meets the definition of a recall. It also says the report can be accessed through weekly publications, search functions and an API (https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/enforcement-reports). This is a public infrastructure for accountability, but it also exposes why a manufacturer cannot treat search as an afterthought. Once a recall record enters regulator search, company wording, product identifiers and public instructions become part of a searchable ecosystem that customers and counterparties use to evaluate the manufacturer.
The openFDA device enforcement API showed 86 device recall records for recalling firms carrying Johnson & Johnson names when queried on July 5, 2026; all were Class II in that query, with 65 terminated and 21 ongoing status values in separate count queries (https://api.fda.gov/device/enforcement.json?search=recalling_firm:%22Johnson%20%26%20Johnson%22&limit=5). The same API returned, among its first records, a 2023 Johnson & Johnson Surgical Vision Class II recall for VERITAS Advanced Infusion Packs and VERITAS Advanced Fluidics Packs, with worldwide distribution and a reason tied to a manufacturing issue that could lead to priming-cycle failure, suboptimal vacuum during surgery, surgical delay or longer surgical time. The record is not a complete measure of J&J's notice performance, and openFDA itself warns its data should be treated as unvalidated. But as public evidence it shows the specificity that a notice economy requires: firm name, product description, quantity, codes, geography, initiation date, classification date, report date and reason.
Drug recall records show similar mechanics. The openFDA drug enforcement API returned 24 drug recall records for Johnson & Johnson-name recalling firms in the queried dataset. Among the first results were 2021 Class II Neutrogena sunscreen spray recalls by Johnson & Johnson Consumer, Inc., with nationwide U.S. distribution and cGMP deviation as the listed reason (https://api.fda.gov/drug/enforcement.json?search=recalling_firm:%22Johnson%20%26%20Johnson%22&limit=5). Some consumer-health businesses later moved outside J&J's current operating perimeter through the Kenvue separation, so older consumer examples should not be read as current portfolio evidence. They remain useful for the notice thesis because they show how a mass-market health product can require quantity, product-code and customer-instruction systems that are costly to run.
Searchability is therefore not a matter of web polish. It is a way to reduce repeated support questions, prevent misidentification, and let counterparties prove that they acted on the official record. The customer who can find the right notice can act faster. The customer who cannot find it calls, delays, improvises or relies on a third party. Each of those alternatives is a cost.
Fraud risk turns the notice into a defensive asset
Product notices exist in the same economy as counterfeit products, phishing messages, fake recall emails and gray-market diversion. A product notice that tells the market to stop using or return a product has value to criminals because it can redirect attention, harvest data or create a false channel for replacements and refunds. In health products, fraud can also damage patient safety by substituting fake products for genuine ones or by persuading customers to ignore official instructions.
J&J's position on counterfeit healthcare products says counterfeit medicines and medical devices put people at risk of adverse events, serious health problems and potentially death, undermine confidence in product quality and safety, and add monitoring and control costs (https://www.jnj.com/policies-reports/our-position-on-counterfeit-healthcare-products). The policy also describes product and packaging security, supply-chain controls, market monitoring, work with regulators and law enforcement, employee training on suspicious-product reporting, digital technologies to detect illicit trade and serialization and traceability for pharmaceutical products.
That policy is not about product notices alone. But it explains why official notices are not separable from anti-counterfeit economics. If a counterfeit product circulates, the authentic manufacturer needs a channel to warn customers. If a fake recall circulates, the authentic manufacturer needs a channel to debunk it. If a product diversion issue arises, the manufacturer needs a way to tell authorized and unauthorized channels apart. If a patient sees a suspicious message, the patient needs an official page and contact route. The official notice is both a safety instruction and a fraud boundary.
The annual report uses similar risk language. It says counterfeit medicines can adversely affect business and reputation by affecting patient confidence in authentic products and potentially resulting in lost sales, product recalls and increased litigation risk (https://www.jnj.com/download/johnson-johnson-2025-annual-report). This is strong filing evidence that counterfeit risk is financially material enough to disclose. It does not quantify the value of any one notice page. It does show that notice credibility, product authenticity and reputation sit inside the same risk category.
Fraud also raises the value of an abuse-contact surface. RDAP records for jnj.com and jnjmedtech.com list registrar abuse channels through Key-Systems. ICANN status-code documentation explains lock statuses as safeguards against unauthorized transfers and updates. These technical details do not stop phishing by themselves. They do raise the cost of domain-level compromise and provide a formal route for abuse reporting. In a product-notice context, that matters because a spoofed destination can look convincing enough to capture distressed customers. Domain control is not a substitute for medical evidence, but medical evidence needs domain control to reach the market safely.
The expensive part of fraud defense is that it cannot be episodic. A company cannot decide to care about authenticity only on the day of a recall. It has to maintain official domains, security programs, vulnerability intake, search presence, brand-protection monitoring, serialization systems and customer education before the bad event occurs. The notice is the moment when this standing expense becomes visible. Customers see a page, an email or a regulator record; they do not see the renewal calendar, the nameserver design, the abuse mailbox, the escalation route or the anti-counterfeit analytics behind it.
This is why the product notice should be understood as a trust cost. It is not a revenue product in the ordinary sense. No hospital wants to buy more notices. But hospitals, clinicians and patients do pay indirectly for a company able to provide authoritative updates when facts change. The payment is embedded in product price, procurement preference, liability tolerance and brand trust. If the notice system fails, the cost appears later as litigation, lost sales, regulator scrutiny, support overload or reputational damage.
Public records show the downside of weak notice economics
The strongest public evidence for product-notice value comes from downside disclosures, not from positive case studies. J&J's annual report states that product concerns can result in safety alerts, field actions, recalls, governmental investigations, regulatory action, claims and lawsuits, fines and settlements, declining sales and reputational damage. It adds that recalls have in the past, and could in the future, lead to government investigations and inspections, manufacturing shutdowns, product shortages, remediation costs, civil penalties and criminal prosecution (https://www.jnj.com/download/johnson-johnson-2025-annual-report). That is strong evidence that the risk category is material. It is not subtle.
The same report's legal notes list product-liability accruals for several historic device and medicine matters, including DePuy ASR hip, PINNACLE acetabular cup, pelvic mesh, hernia-mesh products and ELMIRON claims (https://www.jnj.com/download/johnson-johnson-2025-annual-report). These matters are not all notice failures. Many involve design, warning, causation, scientific disagreement, litigation strategy and market history. But they show the financial environment in which notices operate. When a product concern matures into litigation, every public statement, label update, recall communication and archived notice becomes part of the evidentiary record.
FDA enforcement evidence adds operational detail. The 2023 Surgical Vision recall example from openFDA involved 148,941 VERITAS packs and a stated potential consequence in surgery. The public record includes initiation and classification dates, product descriptions and code information. That is the skeleton of a notice economy: the affected scope has to be defined at enough granularity for customers to locate product, and the reason has to be clear enough for medical and operational teams to assess urgency. It is also evidence of cost. Someone had to trace lots, write letters, manage customer response, coordinate with FDA, publish or preserve records, and handle worldwide distribution.
The FDA guidance on electronic distribution explains why this cannot be solved by simply emailing everyone. It says recall notifications should be effective risk communication, that the communication should reach the intended recipient, that follow-up may be needed, and that proof of receipt or other acknowledgment can assist in determining effectiveness (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-electronic-means-distribute-certain-product-information). That creates a measurable burden. If a distributor does not respond, the company may need more contact. If a hospital receives the message but the relevant department does not, the notice has failed economically even if it succeeded technically. If the recipient cannot connect the lot numbers to inventory records, the notice creates labor without creating action.
Professional media can amplify the downside when safety concerns attach to a strategic product. The Wall Street Journal reported in February 2025 that J&J had halted U.S. sales of the Varipulse heart-rhythm device after reports of neurovascular events, while the company continued to work with regulators and continue commercialization outside the United States (https://www.wsj.com/health/healthcare/j-js-high-hopes-for-heart-rhythm-device-grounded-by-safety-concerns-8ea63120). J&J's 2025 annual report later said the Varipulse platform had been used to treat more than 40,000 atrial fibrillation patients and that MedTech delivered more than 40 regulatory approvals across major markets in 2025 (https://www.jnj.com/download/johnson-johnson-2025-annual-report). The juxtaposition is useful. A notice system is most valuable when a product is commercially important, clinically sensitive and public scrutiny is high. The more strategic the product, the higher the trust cost when safety communication is required.
The evidence therefore supports a conservative claim: in J&J's markets, notices are part of risk containment. The public record does not show that a specific notice saved a specific amount of money. It does show that product concerns can become expensive across sales, litigation, regulation and reputation, and that official communication is one of the mechanisms available to limit that damage.
The notice also serves the counterparty balance sheet
A product notice has a second balance sheet: the customer's. Hospitals, distributors, pharmacies and clinics face their own costs when a notice arrives. They must locate product, freeze inventory, assess patient exposure, brief staff, call customers, respond to auditors and sometimes buy substitutes. They may also face liability if they miss or mishandle the notice. A manufacturer that provides precise, official and durable notice material lowers those costs. A manufacturer that provides vague, scattered or hard-to-authenticate notice material raises them.
This is where the "trust cost" becomes commercially relevant even without direct notice revenue. Procurement teams do not price notices as a separate line item. But they do evaluate supplier reliability, quality history, regulatory performance, customer support and ability to manage field actions. The notice is a test of those attributes under stress. In a competitive market, the company that manages bad news cleanly may preserve future trust better than the company that tries to minimize the notice and leaves counterparties to do the interpretive work.
The annual report's scale matters here. J&J says its subsidiaries operate 63 manufacturing facilities occupying about 10.4 million square feet, with facilities across the United States, Europe, the Western Hemisphere outside the United States, and Africa, Asia and Pacific (https://www.jnj.com/download/johnson-johnson-2025-annual-report). It also uses external manufacturers in addition to its owned and leased sites. That scale makes supplier and manufacturing evidence part of the notice burden. A notice can require tracing not only a final product but also a process, material, software component or supplier path.
J&J's quality position says its audit program applies to facilities that manufacture, store or distribute product, and to external manufacturers that provide materials, products and services. It also says suppliers are audited against quality agreements and relevant regulations (https://www.jnj.com/policies-reports/our-position-on-quality-and-compliance). That governance does not prove every notice works. It does show why the cost is structural. A company cannot write a reliable notice if it does not have records that connect product, process and distribution.
Customer support is another hidden cost. FDA's recall guidance emphasizes a ready means for the recipient to report whether it has the product and, where necessary, follow-up communication. That means the notice must create capacity for replies. A large notice can produce phone calls, emails, portal traffic, forms, returns, replacement requests, adverse-event reports and demands for local-language clarification. The support load is part of the notice cost. It is also part of the notice value, because a message that gives customers no usable response route is not complete risk communication.
Archiving is similarly underappreciated. A notice may need to be consulted after the product is no longer sold, after an acquisition, after a plant has changed, after a webpage has been redesigned or after litigation begins. FDA's public recall page keeps current postings for three years before archive access, while enforcement data and company records can persist in different forms. The manufacturer therefore has to decide how much public notice material to preserve, how to keep old URLs from breaking, and how to distinguish old notices from current instructions. That is information governance, but it is also customer service.
The counterparty benefit is strongest when the notice reduces ambiguity. A distributor that can identify exactly which product is affected avoids freezing unrelated stock. A hospital that can search by lot avoids sweeping procedure delays. A clinician who can see the medical rationale avoids either underreaction or overreaction. A patient who can find the official page avoids counterfeit or rumor channels. Each avoided ambiguity is small in isolation. Across a global product base, the sum becomes economically meaningful. The public evidence supports that logic, although it does not provide the private measurements needed to price it.
Why the public evidence cannot prove full value
The thesis that product notices are worth paying for remains unproven in the narrow quantitative sense. The public record shows risk, process and examples. It does not show outcome metrics. There is no public J&J table that says how many customers opened a notice, how many acknowledged it, how many units were recovered faster because the notice was searchable, how many spoofed messages were blocked, how much support demand fell because the page was clearer, or how many adverse outcomes were avoided.
This absence matters. A company can spend heavily on official destinations, legal review, search architecture, call-center readiness and anti-fraud controls and still publish notices that customers do not find or understand. It can maintain formal governance and still experience fragmentation between corporate, product, regional and regulator pages. It can have domain locks and still face phishing. It can maintain RDAP records and still leave registrant details redacted, which is lawful and common but less satisfying for a user trying to identify a domain owner from public data alone. It can provide security contact channels and still have customers confused by a fake email. Public technical evidence suggests controls; it does not prove user comprehension.
The openFDA evidence also has limits. The API is useful for research, but the API itself warns that data are unvalidated. Records may reflect classification timing, naming conventions, historic corporate structures and regulator data fields rather than the full story of a notice. A count of J&J-name device recalls does not measure notice quality. It measures public records matching a query. The 2023 VERITAS example shows specificity and scale, but it does not reveal how quickly every customer acted or whether the official notice prevented harm.
Company policy evidence has similar limits. J&J's quality, patient-safety, security and anti-counterfeit statements describe programs and principles. They are relevant because they explain why notices are expensive. They are not independent audits of every notice outcome. A serious analysis should give them intermediate weight: stronger than marketing copy when they align with regulatory duties and annual-report risks, weaker than public outcome metrics or third-party audits would be.
Annual-report risk language is strong evidence that the category is material, but it is framed for investors. It describes possible adverse effects and known legal categories, not a complete operational model for product notices. When the filing says product concerns can lead to recalls, litigation, reputation damage and declining sales, it supports the downside case. It does not show which communication investments produced which avoided losses.
The RDAP evidence proves less and more than it might appear. It proves that public registration-data systems expose formal details about domains, registrars, status codes, nameservers and abuse contacts. It shows jnj.com and jnjmedtech.com sitting behind visible registration and DNS arrangements. It also shows redaction and a lack of direct public detail about internal ownership. That is normal in modern registration data, but it means RDAP accountability is not a complete authenticity solution for ordinary patients. Most users will not inspect RDAP. They will rely on search, links, browser cues, institutional portals and familiar domains. RDAP is infrastructure for specialists, security teams and accountability processes; it is not a consumer education tool by itself.
The conclusion must therefore be disciplined. Strong public filings and FDA materials support the claim that product notices are necessary risk-control instruments in J&J's markets. Company policy and technical evidence are consistent with the claim that official digital destinations, domain control, searchability and security add value. Missing metrics leave unproven the stronger claim that the spending produces a measurable return above alternatives. The evidence is enough for a trust-cost thesis, not enough for a full value model.
The trust cost is a price of remaining official
The most important feature of a product notice is not that it tells a company story. It tells the market what the official story is allowed to be at a particular moment, under evidence constraints, legal exposure and public-health duties. That is why the notice is costly. It is produced by functions that often have conflicting incentives: speed, accuracy, liability control, customer reassurance, regulator alignment, search visibility, security and archive durability. A weak notice may be cheaper at publication and more expensive afterward. A strong notice is expensive before publication because it absorbs uncertainty inside the company rather than exporting it to customers.
For J&J, the economics are sharpened by scale and history. The current company is built around Innovative Medicine and MedTech, with high-value products, regulated manufacturing and global clinical use. Its filings disclose safety, recall, litigation, counterfeit, regulatory and cybersecurity risk. Its policies describe quality review, medical-safety governance, information security, counterfeit controls and vulnerability reporting. FDA materials describe how recall and product-safety communications should work, including the acceptability and risk of electronic communication. RDAP and IANA records show the domain-control surface on which official pages depend. Together these materials support the argument that a product notice is not a cheap message. It is a standing capability.
The notice sells no glamour. It sells officialness after the sale. It buys a place where a hospital can verify a lot number, a regulator can compare a company statement to enforcement data, a patient can avoid a fake channel, a distributor can stop shipment, and a future reviewer can reconstruct what was known. It buys the right to be believed when the company has to say something uncomfortable.
The cost is real even when there is no recall. Domains have to be renewed and protected. Security teams have to monitor infrastructure. Quality systems have to preserve traceability. Medical-safety teams have to evaluate signals. Legal and regulatory teams have to maintain templates and judgment. Customer-support teams have to be ready for the day a notice turns from a page into a queue of anxious calls. Anti-counterfeit teams have to watch channels where fake products and fake messages can circulate. Search teams have to keep official pages findable without making safety material look promotional.
Whether the cost is worth paying is partly proven and partly still outside public view. It is proven in the negative: filings, FDA rules and enforcement records show that bad product information can become expensive, and that regulators expect recall communications to do specific work. It is suggested by company and technical evidence: J&J maintains relevant governance and identity controls that are consistent with a serious notice system. It is not proven in full: the public cannot see notice effectiveness, avoided harm or customer trust retention metrics.
That boundary is the right conclusion. Product notices are a trust cost, not a trust guarantee. Johnson & Johnson Services and the wider J&J operating system can make digital notices valuable only if the destination is official, searchable, durable and hard to spoof. Public evidence supports the need for that capability. It leaves the exact payoff unpriced.